Fulcrum Therapeutics (FULC) Shares Outstanding (Weighted Average) (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Shares Outstanding (Weighted Average) data on file, last reported at $76.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $76.2 million, up 21.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.2 million (up 21.98% YoY), and the FY2025 annual result was $63355.0, up 2.21% from the prior year.
• Shares Outstanding (Weighted Average) improved to $76.2 million in Q1 2026 per FULC's latest filing, from $63355.0 in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $76.2 million in Q1 2026 and troughed at $40644.0 in Q1 2022.
• A 5-year average of $33.7 million and a median of $60.8 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) plunged 99.87% in 2022, then soared 148948.27% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $44991.0 in 2022, then surged by 36.27% to $61310.0 in 2023, then advanced by 1.1% to $61984.0 in 2024, then grew by 2.21% to $63355.0 in 2025, then jumped by 120198.32% to $76.2 million in 2026.
• Business Quant data shows FULC's Shares Outstanding (Weighted Average) at $76.2 million in Q1 2026, $63355.0 in Q4 2025, and $62.6 million in Q3 2025.